瑞舒伐他汀联合烟酸治疗对高脂血症患者血脂、颈动脉内中膜厚度及踝肱指数的影响
|
摘要
目的观察瑞舒伐他汀联合烟酸治疗对高脂血症患者血脂、颈动脉内中膜厚度(IMT)及踝肱指数(ABI)的影响。方法 248例高脂血症患者,随机分为强化组(126例)和常规组(122例)。强化组采用瑞舒伐他汀联合烟酸强化治疗,常规组采用瑞舒伐他汀常规治疗。比较两组患者治疗前后血脂水平、IMT与ABI变化情况。结果治疗6个月后,两组患者总胆固醇(TC)及低密度脂蛋白胆固醇(LDL-C)、强化组甘油三酯(TG)较本组治疗前下降,高密度脂蛋白胆固醇(HDL-C)较本组治疗前升高;且强化组患者TC、LDL-C低于常规组, HDL-C高于常规组,差异具有统计学意义(P<0.05)。治疗9个月后,两组患者TC、LDL-C、TG较本组治疗前下降, HDL-C较本组治疗前升高,且强化组患者TC、TG、LDL-C低于常规组, HDL-C高于常规组,差异具有统计学意义(P<0.05)。治疗9个月后,两组患者收缩压、舒张压、脉压差均较本组治疗前降低,差异具有统计学意义(P<0.05);两组收缩压、舒张压、脉压差比较差异无统计学意义(P>0.05)。治疗9个月后,两组患者IMT均较本组治疗前降低, ABI明显升高,且强化组患者IMT(1.06±0.10)mm低于常规组的(1.14±0.08)mm, ABI(0.97±0.16)高于常规组的(0.82±0.12),差异具有统计学意义(P<0.05)。结论瑞舒伐他汀联合烟酸可明显降低LDL-C、TC,有效延缓颈动脉粥样硬化,对预防及治疗心脑血管疾病起着积极的作用。
Objective To observe the effect of rosuvastatin combined with nicotinic acid on blood lipid, carotid intima-media thickness(IMT) and ankle brachial index(ABI) in patients with hyperlipidemia. Methods A total of 248 patients with hyperlipidemia were randomly divided into intensive group(126 cases) and routine group(122 cases). Intensive group was treated with rosuvastatin combined with nicotinic acid, and routine group was treated with conventional therapy of rosuvastatin. Comparison were made on blood lipid, IMT and ABI changes before and after treatment between the two groups. Results After 6 months of treatment, both groups had lower total cholesterol(TC) and low density lipoprotein cholesterol(LDL-C) than those before treatment, and intensive group had lower triglyceride(TG) and higher high density lipoprotein cholesterol(HDL-C) than those before treatment. The intensive group had lower TC and LDL-C than routine group, and higher HDL-C than the routine group. Their difference was statistically significant(P<0.05). After 9 months of treatment, both groups had declined TC, LDL-C and TG and increased HDL-C than those before treatment. The intensive group had lower TC, TG, LDL-C and higher HDL-C than routine group. Their difference was statistically significant(P<0.05). After 9 months of treatment, both groups had declined systolic blood pressure, diastolic blood pressure and pulse pressure difference than those before treatment, and the difference was statistically significant(P<0.05). Both groups had no statistically significant difference in systolic blood pressure, diastolic blood pressure and pulse pressure difference(P>0.05). After 9 months of treatment, both groups had lower IMT and higher ABI than those before treatment. The intensive group had lower IMT as(1.06±0.10) mm than(1.14±0.08) mm in routine group, and higher ABI as(0.97±0.16) than(0.82±0.12) in routine group. Their difference was statistically significant(P<0.05). Conclusion Rosuvastatin and nicotinic acid can significantly reduce LDL-C and TC, effectively delay carotid atherosclerosis, and play an active role in the prevention and treatment of cardiovascular and cerebrovascular diseases.
Objective To observe the effect of rosuvastatin combined with nicotinic acid on blood lipid, carotid intima-media thickness(IMT) and ankle brachial index(ABI) in patients with hyperlipidemia. Methods A total of 248 patients with hyperlipidemia were randomly divided into intensive group(126 cases) and routine group(122 cases). Intensive group was treated with rosuvastatin combined with nicotinic acid, and routine group was treated with conventional therapy of rosuvastatin. Comparison were made on blood lipid, IMT and ABI changes before and after treatment between the two groups. Results After 6 months of treatment, both groups had lower total cholesterol(TC) and low density lipoprotein cholesterol(LDL-C) than those before treatment, and intensive group had lower triglyceride(TG) and higher high density lipoprotein cholesterol(HDL-C) than those before treatment. The intensive group had lower TC and LDL-C than routine group, and higher HDL-C than the routine group. Their difference was statistically significant(P<0.05). After 9 months of treatment, both groups had declined TC, LDL-C and TG and increased HDL-C than those before treatment. The intensive group had lower TC, TG, LDL-C and higher HDL-C than routine group. Their difference was statistically significant(P<0.05). After 9 months of treatment, both groups had declined systolic blood pressure, diastolic blood pressure and pulse pressure difference than those before treatment, and the difference was statistically significant(P<0.05). Both groups had no statistically significant difference in systolic blood pressure, diastolic blood pressure and pulse pressure difference(P>0.05). After 9 months of treatment, both groups had lower IMT and higher ABI than those before treatment. The intensive group had lower IMT as(1.06±0.10) mm than(1.14±0.08) mm in routine group, and higher ABI as(0.97±0.16) than(0.82±0.12) in routine group. Their difference was statistically significant(P<0.05). Conclusion Rosuvastatin and nicotinic acid can significantly reduce LDL-C and TC, effectively delay carotid atherosclerosis, and play an active role in the prevention and treatment of cardiovascular and cerebrovascular diseases.
引文
[1]Diehm C, Lange S. Relationship between lipid parameters and the presence of peripheral arterial disease in elderly patients. Curr Med Res Opin, 2004, 20(12):1873-1875.
[2]刘英.他汀类药物非降脂作用研究进展.河北医药, 2007, 29(6):624-626.
[3]赵春水.颈动脉粥样硬化与脑梗死相关性研究.中国实用神经疾病杂志, 2010, 12(24):16-17.
[4]Wyman RA, Keevil JG, Busse KL, et al. Is the ankle-brachial index a useful screening test for subclinical atherosclerosis in asymptomatic, middle-aged adults?Wmj, 2006, 105(6):50-54.
[5]王东.烟酸联合他汀类药物对老年患者动脉粥样硬化的影响.中外健康文摘, 2013(52):66-67.
[6]曹志伟.瑞舒伐他汀对高脂血症合并颈动脉粥样硬化患者血脂及动脉粥样硬化指标的影响.中国药业, 2016, 25(14):66-68.
[7]文蕾,李辉,王丽.瑞舒伐他汀钙联合硫酸氢氯吡格雷对高脂血症患者颈动脉内膜中层厚度的影响.疑难病杂志, 2014(6):579-581.
[8]张卫东,葛中春,田玉龙,等.瑞舒伐他汀联合阿司匹林对颈动脉粥样硬化患者血脂、血清炎症因子及颈动脉内-中膜厚度的影响.中国新药与临床杂志, 2013(10):829-832.
[9]杨霈龙,王立新,袁芳,等.瑞舒伐他汀对轻中度高血压伴高脂血症患者炎性因子及踝臂指数的影响.临床荟萃, 2015(12):1363-1366.
[2]刘英.他汀类药物非降脂作用研究进展.河北医药, 2007, 29(6):624-626.
[3]赵春水.颈动脉粥样硬化与脑梗死相关性研究.中国实用神经疾病杂志, 2010, 12(24):16-17.
[4]Wyman RA, Keevil JG, Busse KL, et al. Is the ankle-brachial index a useful screening test for subclinical atherosclerosis in asymptomatic, middle-aged adults?Wmj, 2006, 105(6):50-54.
[5]王东.烟酸联合他汀类药物对老年患者动脉粥样硬化的影响.中外健康文摘, 2013(52):66-67.
[6]曹志伟.瑞舒伐他汀对高脂血症合并颈动脉粥样硬化患者血脂及动脉粥样硬化指标的影响.中国药业, 2016, 25(14):66-68.
[7]文蕾,李辉,王丽.瑞舒伐他汀钙联合硫酸氢氯吡格雷对高脂血症患者颈动脉内膜中层厚度的影响.疑难病杂志, 2014(6):579-581.
[8]张卫东,葛中春,田玉龙,等.瑞舒伐他汀联合阿司匹林对颈动脉粥样硬化患者血脂、血清炎症因子及颈动脉内-中膜厚度的影响.中国新药与临床杂志, 2013(10):829-832.
[9]杨霈龙,王立新,袁芳,等.瑞舒伐他汀对轻中度高血压伴高脂血症患者炎性因子及踝臂指数的影响.临床荟萃, 2015(12):1363-1366.